Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 50

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 50
---
 licenses with third parties that we may need in the future, we could lose rights that are important to our business.

We may in the future require licenses to third-party
technology and materials. Such licenses may not be available in the future or may not be available on commercially reasonable terms, or
at all, which could have a material adverse effect on our business and financial condition. We may in the future rely on third parties
from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual
property we license from them. We may have limited control over these activities or any other intellectual property that may be related
to future in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted
in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.
We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer
of the intellectual property rights or defend certain of the intellectual property that may be licensed to us. It is possible that the
licensors’ infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. Even if we acquire
the right to control the prosecution, maintenance, and enforcement of the licensed and sublicensed intellectual property relating to our
diagnostic tests or therapeutic product candidates, we may require the cooperation of our licensors and any upstream licensor, which may
not be forthcoming. Therefore, we cannot be certain that the prosecution, maintenance, and enforcement of such patent rights dependent
on third-party licenses will be in a manner consistent with the best interests of our business. If we or our licensor fail to maintain
such patents, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced
or eliminated, and our right to develop and commercialize any of our diagnostic tests or therapeutic product candidates that are the subject
of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license
from third parties will also apply to patent rights we may own in the future. Further, if we fail to comply with our diligence, development
and commercialization timelines, milestone payments, royalties, insurance, and other obligations under our license agreements, we may
lose our patent rights with respect to such agreement, which would affect our patent rights worldwide.

Our inability to secure any future license agreements
necessary for development of our